title: Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma.
abstract: A trial of melphalan and methyl-gag was undertaken in 16 patients with metastatic renal cell carcinoma. Among 14 evaluable patients, 6 had stabilization of disease. No significant responses were observed. While both drugs have produced occasional responses in renal cancer, their combination shows no therapeutic advantage.
authors.affiliation: Medical Department Institut Gustave-Roussy, Villejuif, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Guimaraes
authors.forename: M
authors.initials: M
authors.lastname: Ghosn
authors.forename: M
authors.initials: M
authors.lastname: Ostronoff
authors.forename: M
authors.initials: M
authors.lastname: Azab
authors.forename: C
authors.initials: C
authors.lastname: Theodore
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage
chemical_list: D008935:Mitoguazone; D008558:Melphalan